Iktos completes acquisition of Synsight to enhance AI-based drug discovery platform
Acquiring Company
Iktos
Acquired Company
Synsight
Description
Iktos, a company specializing in AI and Robotics for new drug design, has acquired Synsight, a French biotech company applying AI and high-content cell imaging to the discovery of novel drug candidates. This acquisition complements Iktos' AI-based drug discovery platform, strengthening its drug discovery value chain and enabling the company to internalize biological testing which has been outsourced until now. The integration will also enable Iktos to launch drug discovery programs targeting PPI’s and RPI’s, addressing major unmet medical needs in various therapeutic areas such as cancer and neurodegenerative diseases.
Who to call at Iktos, and when
When Iktos changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Iktos raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Iktos, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Iktos. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Iktos makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Synsight?
Synsight was acquired by Iktos, based in Paris. The deal was reported on July 8, 2024. Iktos is a French start-up specializing in the development of artificial intelligence (AI) solutions applied to chemical research, more specifically to medicinal chemistry and new drug design. Iktos is privately held and operates in Information Technology.
When did Iktos acquire Synsight?
Iktos's acquisition of Synsight was reported on July 8, 2024. Iktos, a company specializing in AI and Robotics for new drug design, has acquired Synsight, a French biotech company applying AI and high-content cell imaging to the discovery of novel drug candidates. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Synsight do?
We aim to make Drug Discovery faster, cheaper and smarter ! Early-Stage Drug Discovery includes many Design-and-Test cycles. A large Pharma company may go through 25 cycles or more in a single year! It is privately held, operating in Biotechnology, and is based in Evry.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.